A CRITICAL APPRAISAL OF THE CURE TRIAL: ROLE OF CLOPIDOGREL IN NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES
Main Article Content
Keywords
cetylsalicylic acid, acute coronary syndromes, bleeding, clopidogrel, myocardial infarction, platelet aggregation inhibitors
Abstract
Background
A clinical study, the CURE trial, compared the use of clopidogrel/acetylsalicylic acid (ASA) to ASA alone in 12,562 patients with non-ST-segment elevation acute coronary syndromes (ACS). Results of the trial suggested a possible first-line role for the more expensive combination of clopidogrel/ASA.
Objective
To perform a critical appraisal of the CURE trial, to determine the efficacy and safety of the clopidogrel/ASA combination in the management of ACS patients and to describe the population most likely to benefit from this combination.
Methods
A critical appraisal of the CURE trial was conducted.
Results
The CURE trial was found to be of high quality (Jadad score 5/5). An absolute risk reduction (ARR) of 2.1% was seen for the clopidogrel/ASA combination for the first primary outcome (death from cardiovascular causes, non-fatal myocardial infarction (MI), or stroke), compared to ASA alone. A 2.3% ARR was seen for the clopidogrel/ASA combination for the second primary outcome, which included the first primary outcome or refractory ischemia. The clinical benefit appears to have mainly been driven by a reduction in the risk of non-fatal MI. A 1% absolute risk increase (ARI) was observed for major bleeding in the clopidogrel/ASA group. Also, 5.2% of subjects in the clopidogrel/ASA group discontinued their study medication for adverse events other than bleeding, thrombocytopenia or allergy, compared to 3.5% in the ASA group.
Conclusions
We established that the overall quality of the CURE trial was good. Compared to ASA, the clopidogrel/ASA combination reduces the risk of recurrent vascular ischemic events in non-ST elevation ACS patients. The main clinical benefit however appears to be limited to a reduction in the risk of non-fatal MI. This benefit needs to be interpreted in light of the associated increased bleeding risk. Given that the risk of MI is elevated in high-risk ACS patients, the benefit of clopidogrel/ASA combination is expected to outweigh the bleeding hazards for this population. As details of all adverse events were not reported, it was not possible to fully evaluate the safety of use of this intervention.
References
2. Van de Graaff ER, Steinhubl SR. Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med 2000;32(8):561-71.
3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340(2):115-26.
4. Stringer KA, Lopez LM. Uncomplicated myocardial infarction. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 5th ed. Toronto: McGraw-Hill; 2002. p.251-71.
5. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Bethesda (MD): American College of Cardiology; 2002. Available: http://www.acc.org/clinical/guidelines/unstable/un stable.pdf (accessed 2002 May 22).
6. Cardiovascular Disease Division, Population and Public Health Branch, Health Canada. Acute myocardial infarction five year average morbidity rates: hospital separations per 100,000 population: Canada, provinces 1989 - 1993. In: Morbidity surveillance information. Ottawa: The Division; 2002. Available: http://www.hcsc.gc.ca/hpb/lcdc/bcrdd/cardio/amimbb_e.html (accessed 2002 Aug 21).
7. Plavix (clopidogrel bisulfate): 75 mg tablets: platelet aggregation inhibitor [product monograph]. Rev. ed. Markham (ON): Sanofi-Synthelabo Canada; 2002 Apr 9.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-39.
10. Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 2000;7(6):435-41.
11. Second Chinese Cardiac Study (CCS-2). metaRegister of Controlled Trials (mRCT) [database online] 2000 Dec 15. Available: http://www.controlled-trials.com/mrct/ (accessed 2001 Nov 9).
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12.
13. Barrowman NJ. Missing the point (estimate)? Confidence intervals for the number needed to treat. CMAJ 2002;166(13):1676-7. Available: http://www.cmaj.ca/cgi/content/full/166/13/1676.
14. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317(7168):1309-12. Available: http://bmj.com/cgi/content/full/317/7168/1309.
15. Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. [London]: BMJ Books; 2000.
16. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682-7.
17. Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2001;32(12):2948-9.
18. Laine L. Gastrointestinal bleeding. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill; 2001. p.252-4.
19. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001;358(9281):527-33.
20. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published erratum appears in JAMA 2003;289(8):987]. JAMA 2002;288(19):2411-20.
21. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published erratum appears in BMJ 2002;324(7330):141]. BMJ 2002;324(7329):71-86.
22. Ontario drug benefit forulary/comparative drug index no. 38. Toronto: Ministry of Health and Long-Term Care; 2003. Available: http://www.health.gov.on.ca/english/providers/pro gram/drugs/formulary/ed38_0_bk.pdf.
23. Sanofi~Synthelabo. In: PPS pharma [catalog]. Moncton (NB): Total Pricing Systems; 2004. p.411-20.
24. Lamy A, Chrolavicius S, Gafni A, Yusuf S, Zhao F, Jönsson B, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE Study [abstract]. Circulation 2002;106(19 Suppl II):758.
25. Gaspoz J-M, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346(23):1800-6.